Long-term exposure of human endothelial cells to metformin modulates miRNAs and isomiRs

Angelica Giuliani1, Eric Londin2, Manuela Ferracin3

  • 1Department of Clinical and Molecular Sciences, Università Politecnica Delle Marche, Via Tronto 10/A, 60126, Ancona, Italy.

Scientific Reports
|December 14, 2020
PubMed

Insights

Metformin, a diabetes drug, alters microRNA (miRNA) and microRNA isoform (isomiR) patterns in aging human endothelial cells. This reshaping of miRNA/isomiR profiles offers new insights into cellular senescence.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Gerontology

Background:

  • Metformin, a widely used glucose-lowering medication, is increasingly recognized for its anti-senescence properties.
  • Emerging research suggests metformin influences microRNA (miRNA) biogenesis.
  • MicroRNA isoforms (isomiRs) represent sequence variations of canonical miRNAs, potentially altering their function.

Purpose of the Study:

  • To comprehensively analyze the impact of metformin on miRNA and isomiR profiles in human endothelial cells experiencing replicative senescence.
  • To investigate how metformin modulates the expression and relative abundance of specific miRNAs and their isoforms during cellular aging.

Main Methods:

  • Analysis of miRNA and isomiR profiles in human endothelial cells treated with metformin during replicative senescence.
  • Differential expression analysis of miRNAs and isomiRs.
  • Pathway enrichment analysis to identify biological processes affected by metformin-regulated miRNAs and isomiRs.

Main Results:

  • Metformin treatment led to differential expression of 27 miRNAs, including notable examples like miR-100-5p and miR-217.
  • IsomiR analysis revealed that non-canonical sequences constitute a significant portion (nearly 40%) of the miRNA pool.
  • Metformin significantly altered the relative abundance of 133 isomiRs, including non-canonical forms of key miRNAs. Some isomiRs exhibited alternative seed sequences and distinct target profiles compared to canonical forms.
  • Pathway analysis indicated that metformin modulates pathways related to proliferation and nutrient sensing via regulated miRNAs.

Conclusions:

  • Metformin significantly reshapes the senescence-associated miRNA and isomiR landscape in endothelial cells.
  • The study expands the understanding of the molecular mechanisms underlying metformin's anti-senescence effects.
  • The findings highlight the importance of considering isomiRs in miRNA-mediated drug actions and cellular processes like senescence.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
466